Avoro Ventures Fund L.P.
Follow-ons onlyEmerging manager
Follow-ons only: first sale Feb 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $178.42M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Global
01 · Thesis
Avoro Ventures Fund L.P. is the firm's inaugural fund, which reached a final close. It invests in life sciences as a global venture capital firm. Its portfolio includes Vicebio Ltd, a biopharmaceutical company developing novel vaccines against respiratory viral infections.
02 · Initial check
$1.78M to $2.97M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Behzad Aghazadeh, Principal
- Scott Epstein, COO and CCO of Avoro Ventures LLC
04 · Deals
- Vicebio Ltd source
05 · Evidence
Invested in Vicebio Ltd
Vicebio Ltd (“Vicebio”), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio
https://avorocapital.com/news/2024/Avoro Ventures is a global venture capital firm investing in life sciences. Its inaugural fund reached a final close.
Avoro Ventures, a global venture capital firm investing in life sciences
https://avorocapital.com/news/
06 · Sources
Last verified: Oct 25, 2026